Contact this trialFirst, we need to learn more about you.
Contrast-Enhanced Ultrasound for Breast Cancer
Recruiting1 awardPhase 2 & 3
Rochester, Minnesota
This trial uses CEUS to study if a contrast agent can predict how well breast cancer will respond to neoadjuvant chemotherapy. SHAPE is used to estimate pressure in the tumor and surrounding tissues noninvasively. The study hypothesis is that the subharmonic signal difference in the tumor can predict breast cancer response to NAC after 10% of the therapy regimen.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service